Health

Merck KGaA Nears Deal to Buy SpringWorks Therapeutics

Merck KGaA headquarters in Darmstadt, Germany. — Merck KGaA headquarters in Darmstadt, Germany.
Photographer: Jacobia Dahm/Bloomberg

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By Sonja Wind, Michelle F Davis, and Eyk Henning

April 24, 2025 at 7:25 PM UTC

Updated on

April 25, 2025 at 7:17 AM UTC

This article is for subscribers only.

Merck KGaA is nearing a deal to acquire SpringWorks Therapeutics Inc., people familiar with the matter said.

An announcement may come as soon as Monday, the people said, asking not to be identified discussing confidential information. A deal could value SpringWorks at about $3.5 billion, according to one of the people.